Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
RotaTeq- Rotavirus Vaccine, Live, Pentavalent · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | RotaTeq™ |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent | BIOLOGICAL | 2.0 mL oral dose of RotaTeq™. 14 week treatment period |
| Comparator: Placebo | BIOLOGICAL | Arm 2: Placebo. 14 week treatment period |
Inclusion Criteria: * Age 4 weeks through 12 weeks at Dose 1 * Parent able to understand study procedures and give consent Exclusion Criteria: * Clinical evidence of active gastrointestinal disease * Subjects who are currently or expected to participate in other studies of investigational product...
RotaTeq is a vaccine studied for the prevention of rotavirus-related illness, including vomiting, diarrhea, and fever. It is an infectious disease vaccine developed by Merck. The clinical program evaluated it in healthy infants, with the primary study enrolling 7,504 participants.
RotaTeq is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the pentavalent live oral rotavirus vaccine and ran its clinical development program, including the Phase 3 study conducted in developing world settings.
RotaTeq has been evaluated in Phase 3 clinical development. Its single registered trial, NCT00362648, was a Phase 3 study that has been completed. The program included 7,504 enrolled participants, and no trials are currently listed as active.
RotaTeq was studied in the Phase 3 trial NCT00362648, titled Developing World Study for RotaTeq (V260-015). The trial enrolled 7,504 healthy volunteers aged 4 weeks and older, was randomized, double blind, and placebo controlled, and it is now completed.
Yes. RotaTeq is also known as Rotavirus Vaccine, Live, Oral, Pentavalent, sometimes written with the trademark symbol as RotaTeq. These names refer to the same Merck pentavalent live oral rotavirus vaccine, so searches under either name point to the same product.
The RotaTeq Phase 3 trial NCT00362648 was a randomized, double blind, placebo controlled study enrolling 7,504 healthy volunteers. Participants were at least 4 weeks old and of any sex, and the study covered vomiting, diarrhea, and fever. It has been completed.